Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients
Alberto Bottini(University of Genoa), Alfredo Berruti(Surgical Specialties (Canada)), Giuliana Bodini(John Radcliffe Hospital), Paolo Bruzzi(Alleanza Contro il Cancro), Alessandra Bersiga(Istituti Ospitalieri di Cremona), Giovanni Allevi(Istituti Ospitalieri di Cremona), Rossana Dionisio(John Radcliffe Hospital), Maria Pia Brizzi(Ospedale San Luigi Gonzaga), Sergio Aguggini(Istituti Ospitalieri di Cremona), Arianna Montruccoli(John Radcliffe Hospital), Luigi Dogliotti(Aarhus University Hospital), Adrian L. Harris(University of Oxford), Stephen B. Fox(Peter MacCallum Cancer Centre), Manuela Milani(Humanitas University), Claudio Bernardi(John Radcliffe Hospital), Simone Bonardi(Istituti Ospitalieri di Cremona), Daniele Generali(University of Trieste)
Cited by 190
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k